Xenetic Biosciences Inc. Common Stock (XBIO)

FairStock Score: 65/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earning power, honest accounting, and a margin of safety. Xenetic is not that today. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $660,601 and net loss was $929,695. In fiscal Q1 2026, revenue was $806,923 and net loss was $456,382. For FY2025, filed figures show revenue of $3.0M and net loss of $2.7M; FY2024 revenue was $2.5M with a $4.0M loss; FY2023 revenue was $2.5M with a $4.1M loss. FairStock's Lynch category is none because the company lost money in each of the last four years. That is not a record of compounding value; it is a record of consuming capital. The business is an early-stage immune-oncology developer with only 2 employees, so its competitive position depends on science and financing, not on a proven moat. It has no debt, D/E 0.00, which helps, and at the 2026-10-13 close FairStock shows P/B of 0.65, so the shares trade below stated book value. But P/E is -1.83, ROE is -47.04%, ROCE is -26.80%, and trailing free cash flow is -$2.3M, a -47.0% FCF yield. Those figures show the asset base is being spent. Piotroski is 2/9 and Altman is -36.51, both warning signs. A low P/B can be a trap when the assets are cash needed for trials. Without profits, the value rests on pipeline success and future financing, which may dilute owners. I would demand a much larger discount or evidence of self-funding before calling this a true Graham bargain.

In plain English: Xenetic Biosciences is a very small healthcare company trying to develop treatments that help the immune system fight cancer. It is not making a profit: it lost money in recent years, brings in only a few million dollars of revenue, and burns cash. The stock may look cheap next to its stated net worth, but the business itself looks weak and highly uncertain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer